Your new experience awaits. Try the new design now and help us make it even better

SYSTEMATIC REVIEW article

Front. Immunol.

Sec. Multiple Sclerosis and Neuroimmunology

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1659848

This article is part of the Research TopicImmune Responses in Neurodegeneration: Opportunities for Targeted InterventionsView all articles

Research on Parkinson's disease immunotherapy: A bibliometric analysis via multiple databases

Provisionally accepted
  • 1Chengdu Eighth People’s Hospital, Chengdu, China
  • 2West China Hospital of Sichuan University, Chengdu, China
  • 3The Affiliated Hospital of Southwest Medical University, Luzhou, China
  • 4Chengdu Medical College The First Affiliated Hospital, Chengdu, China
  • 5Università di Bologna, Campus di Cesena, Cesena, Italy

The final, formatted version of the article will be published soon.

Background Parkinson's disease (PD) is a neurodegenerative disorder involving degeneration of dopaminergic neurons in the substantia nigra, abnormal aggregation of α-synuclein, and neuroinflammatory response. Although research on PD immunotherapy is advancing rapidly, bibliometric analysis in this field remains underdeveloped. Methods Literature related to "Parkinson's disease" and "immunotherapy" from the Web of Science Core Collection and Scopus was used for data merging and bibliometric analysis via Bibliometrix. The characteristics of the relevant clinical trials in this field retrieved from the PubMed database were summarized, and the study protocols were traced back through the trials registry website. Results After merging the two databases, a total of 890 documents from 488 sources were covered. A total of 3,804 researchers from 1,483 institutions in 63 countries published research in this field. Authors, institutions, and countries/regions were classified into 5, 12, and 13 clusters, respectively. Keywords such as "Parkinson's disease", "immunotherapy", and "alpha-synuclein" were frequently used. The maps of keyword co-occurrence and clusters revealed the generation of two clusters. A total of 8 clinical trials were searched and included. These trials focused on active immunotherapy and targeted antibodies, involving both healthy volunteers and patients with PD. Conclusions The field of PD immunotherapy has vigorous development potential. The current research focus in this field is concentrated on analyzing pathological mechanisms and innovating treatment strategies. Precise immunological intervention techniques are frontiers in this field. In the future, large-scale randomized controlled trials should be conducted to enhance the clinical translation efficiency of immunotherapy.

Keywords: Parkinson's disease, Immunotherapy, Bibliometrics, hotspots, Frontiers

Received: 04 Jul 2025; Accepted: 23 Sep 2025.

Copyright: © 2025 Fei, Wang, Song, Cao, Gao and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Yaqian Gao, 673509366@qq.com
Yue Hu, huyue@swmu.edu.cn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.